The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Anticoagulation in Atrial Fibrillation

심방세동에서의 항응고요법

  • Ko, Jum-Suk (Department of Internal Medicine, Wonkwang University School of Medicine) ;
  • Kim, Nam-Ho (Department of Internal Medicine, Wonkwang University School of Medicine)
  • 고점석 (원광대학교 의과대학 내과학교실) ;
  • 김남호 (원광대학교 의과대학 내과학교실)
  • Published : 2011.10.01
⟨ Previous Next ⟩

Abstract

Atrial fibrillation (AF) is the most commonly occurring arrhythmia. An antithrombotic agent is considered mandatory as part of the management in most patients with AF. It has been conclusively demonstrated that long-term anticoagulation therapy can significantly reduce the risk of stroke in patients with non-valvular AF. While vitamin K antagonists (VKAs) such as warfarin are highly effective, they possess numerous limitations that curtail their use, or make their use challenging for clinicians and patients. A new generation of anticoagulants are being investigated in clinical trials in patients with AF. One or more of these agents have the potential to either replace or act as alternatives to VKA therapy in AF. This review summarizes the recent accumulated evidence on anticoagulation to prevent the thromboembolism in patients with non-valvular AF.

Keywords

References

  1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988. https://doi.org/10.1161/01.STR.22.8.983
  2. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
  3. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-1420. Erratum in: Europace 2011;32:1172. https://doi.org/10.1093/europace/euq350
  4. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:104-123. https://doi.org/10.1161/CIR.0b013e3181fa3cf4
  5. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/ HRS focused update on the management of patients with atrial fibrillation (updateon dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011;57:1330-1337. https://doi.org/10.1016/j.jacc.2011.01.010
  6. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989;1:175-179.
  7. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991;84:527-539. https://doi.org/10.1161/01.CIR.84.2.527
  8. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation: the Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990;323:1505-1511. https://doi.org/10.1056/NEJM199011293232201
  9. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327:1406-1412. https://doi.org/10.1056/NEJM199211123272002
  10. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-355. https://doi.org/10.1016/0735-1097(91)90585-W
  11. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke: EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-1262.
  12. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-2078. https://doi.org/10.1056/NEJMoa0901301
  13. Connolly S, Pogue J, Hart R, et al.Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-1912. https://doi.org/10.1016/S0140-6736(06)68845-4
  14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151. https://doi.org/10.1056/NEJMoa0905561
  15. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891. https://doi.org/10.1056/NEJMoa1009638
  16. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817. https://doi.org/10.1056/NEJMoa1007432
  17. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992. https://doi.org/10.1056/NEJMoa1107039
  18. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-1100. https://doi.org/10.1378/chest.10-0134
  19. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833. https://doi.org/10.1056/NEJMoa021328
  20. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm controlin patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840. https://doi.org/10.1056/NEJMoa021375
  21. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised noninferiority trial. Lancet 2009;374:534-542. https://doi.org/10.1016/S0140-6736(09)61343-X